These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20408822)

  • 1. Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients.
    Hsu CW; Yin PH; Lee HC; Chi CW; Tseng LM
    Breast J; 2010; 16(3):264-70. PubMed ID: 20408822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients.
    Yu M; Zhou Y; Shi Y; Ning L; Yang Y; Wei X; Zhang N; Hao X; Niu R
    IUBMB Life; 2007 Jul; 59(7):450-7. PubMed ID: 17654121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
    Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
    Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer.
    Tseng LM; Yin PH; Chi CW; Hsu CY; Wu CW; Lee LM; Wei YH; Lee HC
    Genes Chromosomes Cancer; 2006 Jul; 45(7):629-38. PubMed ID: 16568452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in copy number and deletion development of mitochondrial DNA in blood cells from breast cancer patients during radiochemotherapy].
    Malakhova LV; Antipova VN; Guliaeva NA; Bezlepkin VG; Gaziev AI
    Vopr Onkol; 2006; 52(4):398-403. PubMed ID: 17024810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues.
    Wang Y; Liu VW; Xue WC; Tsang PC; Cheung AN; Ngan HY
    Gynecol Oncol; 2005 Jul; 98(1):104-10. PubMed ID: 15921730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.
    Weerts MJA; Hollestelle A; Sieuwerts AM; Foekens JA; Sleijfer S; Martens JWM
    Clin Cancer Res; 2017 Aug; 23(16):4735-4743. PubMed ID: 28420722
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin.
    Lebrecht D; Kokkori A; Ketelsen UP; Setzer B; Walker UA
    J Pathol; 2005 Dec; 207(4):436-44. PubMed ID: 16278810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroplasmic mutation of mitochondrial DNA D-loop and 4977-bp deletion in human cancer cells during mitochondrial DNA depletion.
    Lee HC; Hsu LS; Yin PH; Lee LM; Chi CW
    Mitochondrion; 2007; 7(1-2):157-63. PubMed ID: 17280876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells.
    Yu M; Shi Y; Wei X; Yang Y; Zhou Y; Hao X; Zhang N; Niu R
    Toxicol Lett; 2007 Apr; 170(1):83-93. PubMed ID: 17391873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial DNA 4977-bp deletion correlated with reactive oxygen species production and manganese superoxidedismutase expression in gastric tumor cells.
    Wang J; Lü YY
    Chin Med J (Engl); 2009 Feb; 122(4):431-6. PubMed ID: 19302750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
    J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer.
    Darvishi K; Sharma S; Bhat AK; Rai E; Bamezai RN
    Cancer Lett; 2007 May; 249(2):249-55. PubMed ID: 17081685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
    Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
    Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
    Jaremko M; Justenhoven C; Schroth W; Abraham BK; Fritz P; Vollmert C; Illig T; Simon W; Schwab M; Brauch H
    Pharmacogenet Genomics; 2007 Jul; 17(7):529-38. PubMed ID: 17558308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.